Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.

被引：5
|
作者：
Wainberg, Zev A.
Shapiro, Geoffrey
Curigliano, Giuseppe
Leong, Stephen
Kristeleit, Rebecca Sophie
Maqueda, Maria Alsina
Britten, Carolyn D.
Milella, Michele
Middleton, Mark R.
Olszanski, Anthony J.
Vaishampayan, Ulka N.
Lopez-Martin, Jose A.
Gelmon, Karen A.
Brega, Nicoletta
Pierce, Kristen J.
Perea, Rachelle
Houk, Brett Edward
Pathan, Nuzhat
Gollerkeri, Ashwin
Razak, Albiruni R. A.
机构：
[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ist Europeo Oncol, Milan, Italy
[4] Univ Colorado, Ctr Canc, Aurora, CO USA
[5] UCL, Inst Canc, London, England
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Med Univ S Carolina, Charleston, SC 29425 USA
[8] Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy
[9] Oxford NIHR Biomed Res Ctr, Oxford, England
[10] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA
[11] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Hosp 12 Octubre, E-28041 Madrid, Spain
[13] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[14] Pfizer Italia, Milan, Italy
[15] Pfizer Oncol, Groton, CT USA
[16] Pfizer Worldwide Res & Dev, San Diego, CA USA
[17] Pfizer Inc, Carlsbad, CA USA
[18] Pfizer, San Diego, CA USA
[19] Pfizer BioTherapeut, Cambridge, MA USA
[20] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2590
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib
    Wainberg, Zev A.
    Shapiro, Geoffrey
    Curigliano, Giuseppe
    Kristeleit, Rebecca Sophie
    Leong, Stephen
    Alsina, Maria
    Milella, Michele
    Britten, Carolyn D.
    Gelmon, Karen A.
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Lopez-Martin, Jose A.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Perea, Rachelle
    Houk, Brett
    Pathan, Nuzhat
    Razak, Albiruni R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor
    Dehnhardt, Christoph M.
    Venkatesan, Aranapkam M.
    Delos Santos, Efren
    Kaloustian, Semiramis Ayral
    Broojimans, Natasja
    Hollander, Irwin
    Chen, Zecheng
    Lucas, Judy
    Mallon, Robert
    Verheijen, Jeroen
    Zask, Arie
    Khafizofa, Gulnaz
    Bursavich, Matt
    Richard, David
    Mansour, Tarek
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [3] Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX
    Iezzi, Alice
    Caiola, Elisa
    Broggini, Massimo
    TRANSLATIONAL ONCOLOGY, 2016, 9 (05): : 458 - 465
  • [4] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, A.
    DeGraff, W.
    Choudhuri, R.
    Sowers, A. L.
    Thetford, A.
    Cook, J. A.
    Van Waes, C.
    Mitchell, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S196 - S197
  • [5] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, Andrew J.
    DeGraff, William
    Choudhuri, Rajani
    Sowers, Anastasia L.
    Thetford, Angela
    Cook, John A.
    Van Waes, Carter
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2792 - 2801
  • [6] A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors
    Wainberg, Z.
    Tabernero, J.
    Maqueda, M. A.
    Leong, S.
    Del Conte, G.
    Britten, C.
    Brega, N.
    Davis, C.
    Houk, B.
    Pierce, K.
    Vermette, J.
    Siu, L.
    Brana, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 171 - 171
  • [7] A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
    Wainberg, Zev A.
    Alsina, Maria
    Soares, Heloisa P.
    Brana, Irene
    Britten, Carolyn D.
    Del Conte, Gianluca
    Ezeh, Patrick
    Houk, Brett
    Kern, Kenneth A.
    Leong, Stephen
    Pathan, Nuzhat
    Pierce, Kristen J.
    Siu, Lillian L.
    Vermette, Jennifer
    Tabernero, Josep
    TARGETED ONCOLOGY, 2017, 12 (06) : 775 - 785
  • [8] A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
    Zev A. Wainberg
    Maria Alsina
    Heloisa P. Soares
    Irene Braña
    Carolyn D. Britten
    Gianluca Del Conte
    Patrick Ezeh
    Brett Houk
    Kenneth A. Kern
    Stephen Leong
    Nuzhat Pathan
    Kristen J. Pierce
    Lillian L. Siu
    Jennifer Vermette
    Josep Tabernero
    Targeted Oncology, 2017, 12 : 775 - 785
  • [9] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Simon P. Langdon
    Charlene Kay
    In Hwa Um
    Michael Dodds
    Morwenna Muir
    Grant Sellar
    Julie Kan
    Charlie Gourley
    David J. Harrison
    Scientific Reports, 9
  • [10] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Langdon, Simon P.
    Kay, Charlene
    Um, In Hwa
    Dodds, Michael
    Muir, Morwenna
    Sellar, Grant
    Kan, Julie
    Gourley, Charlie
    Harrison, David J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345